See other companies on Welcome to the Jungle
Rani Therapeutics
Biotherapeutics technology company
- 101-200 employees
- Healthcare
- B2B
- Biology
- MedTech
- Berryessa, San Jose, CA
Jump to section
Company mission
To improve the lives of millions of patients suffering from chronic conditions by replacing painful injections with a pill designed to minimize GI discomfort.
12% employee growth in 12 months
Our take
Rani Therapeutics is a company developing oral administration for drugs that would usually be delivered via needle – which is often an uncomfortable and even painful experience. The RaniPill has a coating that allows it to pass through the stomach undigested, instead dissolving in the intestines, which triggers the release of the drug by microneedle injection.
It is generally agreed that both providers and patients prefer oral delivery methods, but so far this has been impossible for large molecule-base treatments. In developing the technology to deliver these treatments orally, Rani Therapeutics has opened up a huge gap in the pharmaceuticals market. It is, however, not alone in this new space - as competitors such as Progenity are developing alternative methods to combat the same problem.
In 2021, Rani Therapeutics went public, although it is worth noting that it failed to make its targets. The company has, however, entered into a $45 million loan agreement that will help fund the continued advancement of its research. The RaniPill has also been successfully tested in humans, meaning Rani has taken a step closer to its ultimate goal of making oral delivery for biotherapeutics a reality.
Freddie
Company Specialist at Welcome to the Jungle
Funding (last 2 of 5 rounds)
Dec 2020
$69m
SERIES E
Feb 2018
$53m
LATE VC
Total funding: $180.5m
This company has top investors
Leadership
Mir Imran
(Executive Chairman)Managing Director at InCube Ventures, and Chairman at InCube Labs.
Talat Imran
(CEO, not founder)Co-founded VentureHealth. Former CEO of Venture Web Partners.